Evidence map›Paper›PMID 27042903›Full record

ReviewContinuum (Minneapolis, Minn.)2016

Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.

Stephen N Gomperts

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Continuum (Minneapolis, Minn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04405596 (Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia), which is not on this map. Cited by 130 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 7 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04405596 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2025 to 2027Enrolled15ConditionsLewy Body DiseaseArmsAmbroxol Hydrochloride, Placebo
3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 7 syntheses or guidelines pooled it, 213 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.Movement disorders : official journal of the Movement Disorder Society · 2022
    Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Thalamic nuclei insights into Alzheimer's disease.bioRxiv : the preprint server for biology · 2026
    Article
  18. Review
  19. Review
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stephen N Gomperts
Massachusetts General Hospital · US

Funding

PET imaging of hyperphosphorylated tau differentiates PSP and CBD from PDR21NS090243 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GOMPERTS, STEPHEN N. · 2014 to 2015
$479k
NINDS NIH HHS 1-R21-NS-090243-01
6 · The paper itself

Abstract

purpose of reviewThis article provides an overview of the clinical features, neuropathologic findings, diagnostic criteria, and management of dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD), together known as the Lewy body dementias. RECENT

findingsDLB and PDD are common, clinically similar syndromes that share characteristic neuropathologic changes, including deposition of α-synuclein in Lewy bodies and neurites and loss of tegmental dopamine cell populations and basal forebrain cholinergic populations, often with a variable degree of coexisting Alzheimer pathology. The clinical constellations of DLB and PDD include progressive cognitive impairment associated with parkinsonism, visual hallucinations, and fluctuations of attention and wakefulness. Current clinical diagnostic criteria emphasize these features and also weigh evidence for dopamine cell loss measured with single-photon emission computed tomography (SPECT) imaging and for rapid eye movement (REM) sleep behavior disorder, a risk factor for the synucleinopathies. The timing of dementia relative to parkinsonism is the major clinical distinction between DLB and PDD, with dementia arising in the setting of well-established idiopathic Parkinson disease (after at least 1 year of motor symptoms) denoting PDD, while earlier cognitive impairment relative to parkinsonism denotes DLB. The distinction between these syndromes continues to be an active research question. Treatment for these illnesses remains symptomatic and relies on both pharmacologic and nonpharmacologic strategies. SUMMARY: DLB and PDD are important and common dementia syndromes that overlap in their clinical features, neuropathology, and management. They are believed to exist on a spectrum of Lewy body disease, and some controversy persists in their differentiation. Given the need to optimize cognition, extrapyramidal function, and psychiatric health, management can be complex and should be systematic.

Indexed as

Disease ManagementAutonomic Nervous System DiseasesCognition DisordersHumansLewy Body DiseaseMental DisordersParkinson DiseaseREM Sleep Behavior Disorder

Identifiers

PMID27042903
PMCPMC5390937
OpenAlexW2336133136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.